The Correction Welfare Society of Korea
April 30, 2026
The Correction Welfare Society Of Korea, Jiwoong Song, Hyunsuk Han
This study aimed to examine the effects of body scan meditation on depression, anxiety, stress, and impulsivity among alcohol-related offenders. A total of 30 inmates from A correctional facility in Jeonbuk Province were randomly assigned to either an experimental group or a control group. The experimental group participated in six sessions of body scan meditation over a two-week period. The...
International journal of psychiatry in clinical practice
April 29, 2026
David Eckert, Siegfried Kasper
The treatment of treatment-resistant depression (TRD) remains a clinical challenge. Pharmacologically, several augmentation options exist. The aim of this study was to present a mechanistically informed and clinically oriented decision-making framework for the established strategies of lithium, quetiapine, and esketamine. We conducted a narrative, non-systematic review, performing a targeted...
Naunyn-Schmiedeberg's archives of pharmacology
April 28, 2026
Yunsheng Liu, Rongde Zhong, Fenyong Yao et al.
Depression is a leading global health burden increasingly linked to dysregulation in glutamatergic signaling. Ionotropic glutamate receptors (iGluRs), including NMDA, AMPA, and kainate subtypes, have emerged as pivotal therapeutic targets. However, the rapid expansion of literature has led to a fragmented research landscape, creating an urgent need for a structured overview. This study aims to...
Zenodo (CERN European Organization for Nuclear Research)
April 27, 2026
Ryan Malone
Treatment-resistant depression (TRD) affects approximately 30% of major depressive disorder(MDD) cases and represents a major unmet clinical need. Ketamine produces rapid antidepressanteffects in TRD, but response is variable and no validated biomarker predicts who will respond.Multiple independent studies have now shown that baseline EEG features -- particularly vigilancestage distribution and...
BMC Psychiatry
April 26, 2026
Sergi López-rodríguez, Cinto Segalàs, Eva Real et al.
BACKGROUND: Patients with obsessive–compulsive disorder (OCD) and comorbid major depressive disorder (MDD) represent a severe subgroup with increased treatment resistance, greater functional impairment, and limited therapeutic options. Intranasal esketamine is a rapidly acting treatment for resistant depression, with emerging interest in potential anti-obsessional effects. However, prospective...
Scientific Reports
April 25, 2026
Audrey G. Evers, Elizabeth C. Stade, Aadesh Salecha et al.
1 citation
Enthusiastic media coverage of psychedelics as a treatment for mental health disorders is perceived as hyped compared to coverage of established treatments. To measure potential hype, we conducted pre-registered analyses comparing media coverage (e.g., newspaper articles) of psychedelics to FDA-approved antidepressants for major depressive disorder and posttraumatic stress disorder. We used...
Psychedelics
April 25, 2026
Juliet Meccia, David Casimir, Sisi Li et al.
Over the past 25 years, the use of 5-MeO-DMT in informal and underground settings has contributed a substantial, yet underrecognized, body of knowledge relating to the efficacy of 5-MeO-DMT in alleviating depressive symptoms. Traditional models of drug development, typically characterized by structured trials and regulatory milestones, rarely consider findings from these alternative routes. The...
Journal of psychopharmacology (Oxford, England)
April 24, 2026
Marco Colizzi, Elisa Morandin, Veronica Croccia et al.
Interleukin-6 (IL-6) has been implicated as a potential predictor of ketamine response in treatment-resistant depression (TRD). Esketamine, the S-enantiomer of ketamine, produces rapid antidepressant effects and offers improved safety and intranasal administration. To examine whether baseline IL-6 predicts treatment response to esketamine in individuals with TRD. Fourteen adults with TRD...
Pharmaceuticals (Basel, Switzerland)
April 24, 2026
Pietro Carmellini, Alessandro Cuomo, Maria Beatrice Rescalli et al.
Background/Objectives: Major depressive disorder (MDD) remains a leading cause of disability worldwide and exhibits substantial biological heterogeneity that is not adequately captured by current symptom-based diagnostic systems. While the classical monoamine hypothesis has historically guided antidepressant development, it does not fully account for variability in treatment response, delayed...
Translational Psychiatry
April 24, 2026
Matt Butler, Ellen Moore, James Rucker et al.
1 citation
Hallucinogen persisting perception disorder (HPPD) is characterised by episodes of altered perception linked to past psychoactive drug use, accompanied by distress and functional impairment. To date, clinical characterisation has been limited in scale. Using TriNetX, a global federated health research network of electronic health records, we conducted a retrospective cohort study comparing...
Journal of Psychoactive Drugs
April 23, 2026
Brayan Jonas Mano-Sousa, Maria Clara Gama Fontes, Ana Clara Anacleto Gonçalves et al.
Suicide, particularly in treatment-resistant depression (TRD), remains a pressing global health issue, with over 700,000 annual deaths. Existing treatments often have limited efficacy and delayed onset, creating a need for rapid-acting interventions. Ayahuasca, a traditional Amazonian psychedelic, has shown potential for rapidly reducing suicidal ideation. Our systematic review evaluated the...
Current Pain and Headache Reports
April 21, 2026
Navy C Coggins, Hanson A Chokr, Tricia A Meyer et al.
PURPOSE OF REVIEW: Ketamine was originally developed as a dissociative anesthetic and has remained a valuable agent in anesthesia related to its ability to preserve airway reflexes and relative hemodynamic stability. Over time, its clinical applications have expanded beyond procedural sedation to include roles in pain management and psychiatry. In pain medicine, the therapeutic rationale is...
Scientific Reports
April 21, 2026
Rong Ding, Daojie Wang, Guoxin Wang et al.
Elderly colorectal cancer (CRC) patients face high risks of postoperative depression state, inadequately addressed by opioid-based analgesia. Esketamine, an NMDA receptor antagonist with rapid antidepressant effects, offers potential benefits but lacks evidence in this population. This double-blind RCT enrolled 99 elderly (≥ 65 years) CRC resection patients, randomized to three postoperative...
Mental Wellness
April 21, 2026
Mohsen Khosravi, Domenico de Berardis, Massimo Tusconi
This systematic review and meta-analysis synthesized data from 13 clinical trials (n=606) evaluating psilocybin-assisted psychotherapy for major depressive disorder and treatment-resistant depression. Despite early enthusiasm, the pooled standardized mean difference (-0.79, 95% confidence interval: -3.98 to 2.40, p=0.63) revealed no statistically significant overall antidepressant effect, with...
Open Access Indonesian Journal of Medical Reviews
April 21, 2026
Siti Nashria Rusdhy, Andrian Fajar Kusumadewi, Carla Raymondalexas Marchira et al.
Psilocybin-assisted therapy shows promise for depression, though current evidence relies on Phase 2 trials with notable methodological limitations. We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) evaluating psilocybin-assisted therapy for major or treatment-resistant depression up to February 2024. We evaluated depressive symptom severity using...
Clinical and Preventive Medicine
April 20, 2026
Mykola Didukh, K. Freytag, Vitalii Lunov et al.
Introduction. Following the full-scale Russian invasion of Ukraine, there has been a substantial increase in the need for accessible, rapid-acting, and non-pharmacological approaches to alleviate symptoms of post-traumatic stress disorder and depression among Ukrainian refugees. One potentially useful intervention is the Transcendental Meditation program. Aim. To assess the effectiveness of the...
Brain Sci
April 18, 2026
Longitudinal Effects of Mindfulness Combined with Gratitude Touch on Anxiety, Depression, and Stress: A 12-Month Portable EEG-Based Study.
bioRxiv : the preprint server for biology
April 17, 2026
Pasha A. Davoudian, Quan Jiang, Cory A. Knox et al.
Psychedelics show therapeutic potential for treating psychiatric disorders. While studies have emphasized the roles of cortical pyramidal cells, GABAergic neurons also express serotonin receptors and are therefore likely targets of psychedelics. In this study, we determine the effect of psilocybin on the activity dynamics of major GABAergic cell types in the mouse medial frontal cortex....
Current Neuropharmacology
April 16, 2026
Xiangying Wei, Shan Xu, Zhaoqiong Zhu
Depression represents a critical global health burden, ranking as the second leading cause of disability worldwide. Although drug therapies remain an important cornerstone in treating depression, we must acknowledge their significant shortcomings: they often take too long to work, cause difficult side effects, and fail to prevent relapse. Critically, while current drugs target specific...
Journal of psychopharmacology (Oxford, England)
April 16, 2026
Minna Chang, Allan H. Young, Mario F Juruena
Previous systematic reviews and meta-analyses have reported impressive antidepressant effects of ketamine in treatment-resistant depression (TRD). While ketamine has been compared with electroconvulsive therapy (ECT), the gold standard treatment, the extent and durability of its antidepressant effects over longer periods remain unclear. To our knowledge, this is the first systematic review...
Journal of Intensive Care Medicine
April 16, 2026
Vrutti Patel, Saurabh Sujanyal, Lekhya Raavi et al.
BackgroundKetamine has demonstrated efficacy in treatment-resistant depression, primarily in psychiatric or outpatient populations. Its use in ICU patients remains underexplored, with limited data beyond case reports and small series. This study evaluated the association between subanesthetic ketamine infusions and improvement in depressive symptoms and hemodynamic changes in ICU...
Journal of Affective Disorders
April 15, 2026
Gia Han Le, Sabrina Wong, Danica E. Johnson et al.
4 citations
Ketamine and esketamine exhibit rapid antidepressant effects in persons with treatment-resistant depression (TRD) and bipolar depression (TRBD). However, the synaptic mechanisms governing dose, frequency, and durability of response remain unclear. This review aims to evaluate the dosing parameters, including minimum dose and optimal dosing intervals, that reliably induce or maintain long-term...
Journal of Affective Disorders
April 15, 2026
Jen-Ping Chen, Chih-Wei Hsu, Yi-Ting Chen et al.
Repetitive transcranial magnetic stimulation (rTMS) and esketamine are FDA-approved treatments for treatment-resistant depression (TRD), yet head-to-head comparative effectiveness data remain limited. Our study compared the effectiveness and safety profiles of rTMS versus esketamine in adults with TRD. This cohort study used target trial emulation with 1:1 propensity score matching on 50...
Frontiers in Psychiatry
April 13, 2026
Craig F. Ferris
For the past half-century, psychiatric drug development has largely focused on tweaking neurotransmitter receptors and chemical pathways. Yet despite billions of dollars invested and major advances in neuroscience, truly innovative treatments for mental illness remain scarce. Disorders like depression, schizophrenia, and post-traumatic stress disorder (PTSD) continue to be managed with drugs...